SynthesisFrontiers in immunology2026
The association between systemic lupus erythematosus and cognitive impairment or dementia: a meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs, with neuropsychiatric manifestations, particularly cognitive impairment, being common and debilitating. However, the risk of cognitive decline and dementia in SLE patients remains debated due to methodological differences across studies. Objective: This meta-analysis aims to quantify the association between neurocognitive impairment and dementia in SLE patients by integrating data from observational studies. Methods: We systematically searched PubMed, Embase, and the Cochrane Library from inception to September 2025 for observational studies investigating the association between SLE and all-cause dementia or cognitive impairment. Study quality was assessed using the Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality checklist. Pooled effect estimates were computed using random-effects models. Heterogeneity was assessed with the I² statistic, and pre-specified subgroup analyses were performed. Results: Seven studies involving over 7 million participants were included. The meta-analysis showed a significant association between SLE and cognitive impairment, with a pooled OR (Odds Ratio) of 1.53 (95% CI: 1.26-1.85, p < 0.001), indicating a 53% higher odds. Subgroup analyses found this association in cohort studies (OR = 1.50, 95% CI: 1.20-1.88), as well as in both Asian (OR = 1.56, 95% CI: 1.08-2.26) and non-Asian populations (OR = 1.49, 95% CI: 1.36-1.64), and in both men (OR = 1.43, 95% CI: 1.13-1.80) and women (OR = 1.98, 95% CI: 1.25-3.15). Sensitivity analyses confirmed the robustness of these findings. Conclusion: SLE is associated with significantly higher odds of neurocognitive impairment, underscoring the need for integrated cognitive screening and proactive management in clinical practice. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251148236.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.